Endogeneous repair factor production promoters
It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.
1. A method of treating diseases, said diseases selected from the group consisting of:
ischemic organ disease selected from the group consisting of arteriosclerosis obliterans and cerebral infarction;
liver disease selected from the group consisting of fluminant hepatitis, acute hepatitis and fatty liver;
kidney disease selected from the group consisting of acute renal insufficiency and chronic renal insufficiency;
pancreas disease selected from the group consisting of diabetes mellitus and chronic pancreatitis;
digestive organ disease selected from the group consisting of duodenal ulcer;
nerve degeneration disease selected from the group consisting of stroke;
diabetic complication selected from the group consisting of diabetic nerve disorder and diabetic nephropathy;
vascular endothelial cell disease which is restenosis after PTCA (percutaneous transluminal coronary angiopathy); and
heart disease selected from the group consisting of dilated cardiomyopathy;
comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7, 8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof.
2. A method of treating chronic renal insufficiency, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof.
3. A method of treating dilated cardiomyopathy, comprising administering to a patient in need of treatment an effective amount of (E)[-5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof.
4. A method of treating diseases, said diseases selected from the group consisting of:
ischemic organ disease selected from the group consisting of arteriosclerosis obliterans and cerebral infarction;
liver disease selected from the group consisting of fluminant hepatitis, acute hepatitis and fatty liver;
kidney disease selected from the group consisting of acute renal insufficiency and chronic renal insufficiency;
pancreas disease selected from the group consisting of diabetes mellitus and chronic pancreatitis;
digestive organ disease selected from the group consisting of duodenal ulcer;
nerve degeneration disease selected from the group consisting of stroke;
diabetic complication selected from the group consisting of diabetic nerve disorder and diabetic nephropathy;
vascular endothelial cell disease which is restenosis after PTCA (percutaneous transluminal coronary angiopathy); and
heart disease selected from the group consisting of dilated cardiomyopathy;
comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof whereby production of VEGF and/or HGF is accelerated.
5. A method of treating chronic renal insufficiency, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof whereby production of VEGF and/or HGF is accelerated.
6. A method of treating dilated cardiomyopathy, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof whereby production of VEGF and/or HGF is accelerated.